Who
Mark Froimson
Director
Company insider
Files Form 4 as: Director, Pacira BioSciences.
In numbers
- Trades disclosed
- 29
- Buys
- 2
- Sells
- 3
- Bought
- $20K
- Sold
- $134K
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 14 Jun 2017
- Last trade
- 10 Jun 2026
- Last filed
- 12 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —10,891 at $0.00 | filing |
| 10 Jun 2026filed 12 Jun 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,405 at $0.00 | filing |
| 17 Mar 2026filed 19 Mar 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $11K500 at $21.81 | filing |
| 17 Mar 2026filed 19 Mar 2026 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $11K500 at $21.81 | filing |
| 11 Jun 2025filed 13 Jun 2025 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —11,279 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —6,163 at $0.00 | filing |
| 12 Aug 2024filed 12 Aug 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Bought | $16K1,400 at $11.58 | filing |
| 12 Jun 2024filed 13 Jun 2024 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,179 at $0.00 | filing |
| 12 Jun 2024filed 13 Jun 2024 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —5,230 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —12,925 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —1,775 at $0.00 | filing |
| 8 Jun 2022filed 8 Jun 2022 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —8,225 at $0.00 | filing |
| 8 Jun 2022filed 8 Jun 2022 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —1,160 at $0.00 | filing |
| 9 May 2022filed 11 May 2022 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $59K1,000 at $59.37 | filing |
| 17 Dec 2021filed 20 Dec 2021 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code G | —400 at $0.00 | filing |
| 9 Jun 2021filed 11 Jun 2021 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Code A | —1,066 at $0.00 | filing |
| 9 Jun 2021filed 11 Jun 2021 | PCRX Pacira BioSciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —7,626 at $0.00 | filing |
| 15 Mar 2021filed 17 Mar 2021 | PCRX Pacira BioSciencesPharmaceuticals | SEC FORM 4 Sold | $53K734 at $72.26 | filing |
News
Pacira BioSciences (NASDAQ:PCRX) Upgraded at JPMorgan Chase & Co.PCRX · themarketsdaily.com · 11 Oct 2026Insider Selling: Pacira BioSciences (NASDAQ:PCRX) SVP Sells $217,920.00 in StockPCRX · themarketsdaily.com · 10 Oct 2026Pacira BioSciences jumps 44% on Viatris acquisition deal (PCRX:NASDAQ)PCRX · seekingalpha.com · 8 Oct 2026
0 headlines in the last 90 days name Mark Froimson; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.